Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
SC TC EN
SC TC EN
Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
Vancocin®

Product List
Product Overview
Guideline Recommendations
Vancocin®

Vancomycin Hydrochloride for Injection

The most extensive indications
With eleven approved indications, vancomycin is the primary agent used to treat serious, multidrug-resistant Gram-positive infections across many body sites.
The most extensive indications
Clinically Proven Potency with a Well-Established Safety Profile
Vancomycin exerts potent and sustained bactericidal activity through a unique triple mechanism of action. MRSA and MRCNS exhibit zero drug resistance to vancomycin,according to CHINET data, while Enterococci shows very low resistance rates.
With widely adopted Therapeutic Drug Monitoring (TDM), clinicians can effectively monitor and manage the safety of vancomycin therapy.
Clinically Proven Potency with a Well-Established Safety Profile
Guideline-Recommended First-Line Therapy
Numerous domestic and international guidelines and consensuses recommend vancomycin as the first-line therapy for multidrug-resistant gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA).
Guideline-Recommended First-Line Therapy
The following product information is intended for use by healthcare professionals only.
The following product may not have been approved and/or licensed for marketing in all countries where this website is accessible.
Vancocin®
Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Product information stated by NMPA in Approved Drug Catalog of China.
【Drug Name】

Generic Name: Vancomycin Hydrochloride for Injection

Brand Name： Vancocin®（稳可信®）

Chinese Pinyin: ZHU SHE YONG YAN SUAN WAN GU MEI SU

【Ingredients】

Active Ingredient: Vancomycin

Excipients：Mannitol, hydrochloric acid, water for injection, nitrogen gas.

【Description】

This product is a white or off-white lyophilized block.

【Indications】

For infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other bacteria: Bacteremia, Infective Endocarditis, Osteomyelitis, Arthritis, Secondary superficial infections (e.g., of surgical wounds), Pneumonia, Lung abscess, Empyema, Peritonitis, Meningitis.

【Specifications】

500mg

For detailed product information, please download the full package insert (PDF).
Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Guideline Recommendations
Skin and soft tissue infections

Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue
Infections: 2014 Update by the Infectious Diseases Society of America

2018 WSES/SIS-E Consensus Conference: Recommendations for the Management of Skin and Soft-Tissue Infections

Surgical Infection Society 2020 Updated Guidelines on the Management of Complicated Skin and Soft Tissue Infections

Pneumonia

Management of Adults With Hospital-acquired andVentilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

Guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia 2017 ERS

Chinese Guidelines for the Diagnosis and Treatment of HAP/VAP in Adults 2018

Pneumonia (hospital-acquired): antimicrobial prescribing 2019 NICE

Bacteremia

The Johns Hopkins Antibiotic Guide 2015–2016

Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)

Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK

Central Nervous System Infections

2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis

Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK

Chinese Expert Consensus on the Diagnosis and Treatment of Neurosurgical CNS Infections 2021

Chinese Expert Consensus on the Diagnosis and Treatment of Central Nervous System Infections After Endoscopic Trans nasal Skull Base Surgery 2022

Febrile Neutropenia

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer: 2010 Update by the Infectious Diseases Society of America

Guidelines for Clinical Application of Antibacterial Drugs 2015

Chinese Guidelines for the Clinical Application of Antibacterial Drugs in Patients With Febrile Neutropenia 2020

Intra-Abdominal Infections

Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection

Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Common Surgical Intra-Abdominal Infections 2021

The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 Update

Osteoarticular Infections

Chinese Guidelines for the Diagnosis and Treatment of Periprosthetic Joint Infections 2021

Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics

Manual of Diagnosis and Treatment of Drug-Resistant Gram-Positive Bacterial Infections (2nd Edition)

Infective Endocarditis

Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK

Manual of Diagnosis and Treatment of Drug-Resistant Gram-Positive Bacterial Infections (2nd Edition)

2023 ESC Guidelines for the Management of Endocarditis

Complicated Urinary Tract Infections (cUTIs)

Chinese Expert Consensus on the Diagnosis and Treatment of Urinary Tract Infections-Complicated Urinary Tract Infections 2015

Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK

Manual of Diagnosis and Treatment of Drug-Resistant Gram-Positive Bacterial Infections (2nd Edition)

Technology Platforms
Product Center
About Us
Full Value Chain
News
Investor Relations
Contact Us

沪ICP备2021007464号

Copyright © 2025 design by EDDING

药监局备案号: (沪) -非经营性-2021-0038